Vienna - Delayed Quote EUR

Johnson & Johnson (JNJ.VI)

135.98
-0.56
(-0.41%)
At close: April 24 at 5:32:16 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
89,331,000
88,821,000
85,159,000
79,990,000
78,740,000
Cost of Revenue
28,317,000
27,471,000
26,553,000
24,596,000
23,402,000
Gross Profit
61,014,000
61,350,000
58,606,000
55,394,000
55,338,000
Operating Expense
38,839,000
39,201,000
35,197,000
34,381,000
34,395,000
Operating Income
22,175,000
22,149,000
23,409,000
21,013,000
20,943,000
Net Non Operating Interest Income Expense
496,000
577,000
489,000
214,000
-130,000
Other Income Expense
3,927,000
-6,045,000
-8,802,000
-1,868,000
-1,635,000
Pretax Income
26,604,000
16,687,000
15,062,000
19,359,000
19,178,000
Tax Provision
4,794,000
2,621,000
1,736,000
2,989,000
1,377,000
Net Income Common Stockholders
21,810,000
14,066,000
35,153,000
17,941,000
20,878,000
Diluted NI Available to Com Stockholders
21,810,000
14,066,000
35,153,000
17,941,000
20,878,000
Basic EPS
9.06
5.84
14.60
6.86
7.93
Diluted EPS
8.99
5.79
13.72
6.73
7.81
Basic Average Shares
2,407,050
2,407,300
2,407,078
2,613,597
2,628,965
Diluted Average Shares
2,427,825
2,429,400
2,560,400
2,663,900
2,674,000
Total Expenses
67,156,000
66,672,000
61,750,000
58,977,000
57,797,000
Net Income from Continuing & Discontinued Operation
21,810,000
14,066,000
35,153,000
17,941,000
20,878,000
Normalized Income
19,594,896.26
20,089,235
21,292,770
17,265,068
18,830,152
Interest Income
1,300,000
1,332,000
1,261,000
490,000
53,000
Interest Expense
804,000
755,000
772,000
276,000
183,000
Net Interest Income
496,000
577,000
489,000
214,000
-130,000
EBIT
27,408,000
17,442,000
15,834,000
19,635,000
19,361,000
EBITDA
34,704,000
24,781,000
23,320,000
26,605,000
26,751,000
Reconciled Cost of Revenue
28,317,000
27,471,000
26,553,000
24,596,000
23,402,000
Reconciled Depreciation
7,296,000
7,339,000
7,486,000
6,970,000
7,390,000
Net Income from Continuing Operation Net Minority Interest
21,810,000
14,066,000
13,326,000
16,370,000
17,801,000
Total Unusual Items Excluding Goodwill
2,702,000
-7,145,000
-9,002,000
-1,058,000
-1,109,000
Total Unusual Items
2,702,000
-7,145,000
-9,002,000
-1,058,000
-1,109,000
Normalized EBITDA
32,002,000
31,926,000
32,322,000
27,663,000
27,860,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
486,896.26
-1,121,765
-1,035,230
-162,932
-79,848
12/31/2021 - 5/23/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SNW.HM Sanofi SA
93.40
+0.33%
 
LLY.MX Eli Lilly and Company
16,785.00
+4.25%
 
LLY0.DU Eli Lilly and Co
19.60
+2.08%
 
GRF.MC Grifols, S.A.
8.45
+0.64%
 
GSK GSK plc
37.50
+1.27%
 
AMGN Amgen Inc.
279.84
+0.70%
 
BMY Bristol-Myers Squibb Company
48.69
+0.33%
 
ABBV AbbVie Inc.
180.37
+1.88%
 
PFE Pfizer Inc.
22.78
+1.74%
 
NVO Novo Nordisk A/S
62.63
+2.17%